Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

JERUSALEM, Nov. 14, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel’s Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its […]

Categories: Press Releases|Tags: |

Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

JERUSALEM, Oct. 31, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader […]

Categories: Press Releases|Tags: |

Oramed to Present at the Diabetes Technology Meeting

JERUSALEM, October 24, 2017 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th Annual Diabetes Technology Meeting, November 2 to November 4, 2017, […]

Categories: Press Releases|Tags: |

Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists

JERUSALEM, Oct. 17, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the publication of a new paper co-authored by Oramed’s Chief Scientific Officer, Dr. Miriam Kidron, Dr. Roy Eldor, Dr. […]

Categories: Press Releases|Tags: |

Oramed to Present at the Disruptive Growth Showcase Conference

JERUSALEM, Sept. 25, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 2017 Disruptive Growth Company Showcase NYC Conference, taking place September […]

Categories: Press Releases|Tags: |

Oramed Announces Successful Meeting with FDA for Oral Insulin

JERUSALEM, Sept. 5, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, […]

Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, August 29, 2017 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 19th Annual Global Investment Conference, taking place on […]

Categories: Press Releases|Tags: |

Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

JERUSALEM, July 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs.

“We are very pleased to welcome Dr. […]

Categories: Press Releases|Tags: |

Oramed to Present at BIT’S 5th World Congress of Diabetes on July 13, 2017

JERUSALEM, July 12, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, will deliver a presentation titled, “Oral Insulin for Diabetes Treatment: […]

Categories: Press Releases|Tags: |

Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

JERUSALEM, July 11, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed […]

Categories: Press Releases|Tags: |